$REPH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Recro Pharma, Inc.. Get notifications about new insider transactions in Recro Pharma, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Grant | A | 0.00 | 26,923 | 0 | 26,923 | 0 to 26.9 K |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Grant | A | 0.00 | 26,923 | 0 | 84,982 | 58.1 K to 85 K (+46.37 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 26,923 | 0 | 67,429 | 40.5 K to 67.4 K (+66.47 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Grant | A | 0.00 | 26,923 | 0 | 226,574 | 199.7 K to 226.6 K (+13.49 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Grant | A | 0.00 | 26,923 | 0 | 77,982 | 51.1 K to 78 K (+52.73 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 26,923 | 0 | 76,546 | 49.6 K to 76.5 K (+54.26 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 26,923 | 0 | 80,280 | 53.4 K to 80.3 K (+50.46 %) |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Apr 12 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 3.24 | 5,172 | 16,757 | 376,564 | 381.7 K to 376.6 K (-1.35 %) |
| Feb 12 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Option Exercise | M | 4.06 | 20,000 | 81,200 | 20,000 | |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 3.03 | 1,352 | 4,097 | 382,811 | 384.2 K to 382.8 K (-0.35 %) |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Payment of Exercise | F | 3.03 | 6,816 | 20,652 | 199,651 | 206.5 K to 199.7 K (-3.30 %) |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Buy | M | 0.00 | 5,000 | 0 | 206,467 | 201.5 K to 206.5 K (+2.48 %) |
| Jan 12 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 2.99 | 12,610 | 37,704 | 384,163 | 396.8 K to 384.2 K (-3.18 %) |
| Jan 12 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 30,000 | 0 | 396,773 | 366.8 K to 396.8 K (+8.18 %) |
| Jan 12 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 200,000 | 0 | 366,773 | 166.8 K to 366.8 K (+119.92 %) |
| Jan 12 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 36,000 | 0 | 166,773 | 130.8 K to 166.8 K (+27.53 %) |
| Jan 05 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 3.09 | 1,210 | 3,739 | 130,773 | 132 K to 130.8 K (-0.92 %) |
| Dec 28 2020 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 3.17 | 18,830 | 59,691 | 701,017 | 719.8 K to 701 K (-2.62 %) |
| Dec 28 2020 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 3.17 | 56,375 | 178,709 | 2,097,938 | 2.2 M to 2.1 M (-2.62 %) |
| Dec 22 2020 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 3.03 | 6,208 | 18,813 | 719,847 | 726.1 K to 719.8 K (-0.86 %) |
| Dec 22 2020 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 3.03 | 18,587 | 56,326 | 2,154,313 | 2.2 M to 2.2 M (-0.86 %) |
| Dec 18 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | A | 3.03 | 116,505 | 353,010 | 116,505 | |
| Dec 18 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 79,208 | 0 | 131,983 | 52.8 K to 132 K (+150.09 %) |
| Dec 18 2020 | REPH | Recro Pharma, Inc. | ENLOE J DAVID JR | Chief Executive Off ... | Option Exercise | A | 3.03 | 194,175 | 588,350 | 194,175 | |
| Dec 18 2020 | REPH | Recro Pharma, Inc. | ENLOE J DAVID JR | Chief Executive Off ... | Grant | A | 0.00 | 132,013 | 0 | 151,815 | 19.8 K to 151.8 K (+666.66 %) |
| Dec 18 2020 | REPH | Recro Pharma, Inc. | ENLOE J DAVID JR | Chief Executive Off ... | Grant | A | 0.00 | 19,802 | 0 | 19,802 | 0 to 19.8 K |
| Dec 09 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 2.30 | 7,611 | 17,505 | 52,775 | 60.4 K to 52.8 K (-12.60 %) |
| Dec 09 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 2.30 | 34,128 | 78,494 | 207,066 | 241.2 K to 207.1 K (-14.15 %) |
| May 11 2020 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
| May 11 2020 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Grant | A | 0.00 | 8,363 | 0 | 23,757 | 15.4 K to 23.8 K (+54.33 %) |
| May 11 2020 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
| May 11 2020 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Grant | A | 0.00 | 8,363 | 0 | 58,059 | 49.7 K to 58.1 K (+16.83 %) |
| May 11 2020 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
| May 11 2020 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 8,363 | 0 | 40,506 | 32.1 K to 40.5 K (+26.02 %) |
| May 11 2020 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
| May 11 2020 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 8,363 | 0 | 53,357 | 45 K to 53.4 K (+18.59 %) |
| May 11 2020 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
| May 11 2020 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 8,363 | 0 | 49,623 | 41.3 K to 49.6 K (+20.27 %) |
| May 11 2020 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
| May 11 2020 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Grant | A | 0.00 | 8,363 | 0 | 51,059 | 42.7 K to 51.1 K (+19.59 %) |
| Apr 20 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Sell | S | 8.22 | 80,000 | 657,600 | 161,194 | 241.2 K to 161.2 K (-33.17 %) |
| Feb 05 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | A | 16.62 | 45,000 | 747,900 | 45,000 | |
| Feb 05 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 12,000 | 0 | 58,738 | 46.7 K to 58.7 K (+25.68 %) |
| Feb 05 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | A | 16.62 | 45,000 | 747,900 | 45,000 | |
| Feb 05 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 12,000 | 0 | 58,738 | 46.7 K to 58.7 K (+25.68 %) |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 16.38 | 1,095 | 17,936 | 46,738 | 47.8 K to 46.7 K (-2.29 %) |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 5,000 | |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 16.38 | 5,552 | 90,942 | 241,194 | 246.7 K to 241.2 K (-2.25 %) |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 246,746 | 241.7 K to 246.7 K (+2.07 %) |
| Jan 03 2020 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 17.53 | 979 | 17,162 | 47,833 | 48.8 K to 47.8 K (-2.01 %) |
| Jan 03 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 17.53 | 4,945 | 86,686 | 241,746 | 246.7 K to 241.7 K (-2.00 %) |
| Dec 16 2019 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Grant | A | 0.00 | 11,071 | 0 | 39,283 | 28.2 K to 39.3 K (+39.24 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 17,283 | 0 | 48,812 | 31.5 K to 48.8 K (+54.82 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 13,848 | 0 | 41,260 | 27.4 K to 41.3 K (+50.52 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 17,582 | 0 | 44,994 | 27.4 K to 45 K (+64.14 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Grant | A | 0.00 | 15,284 | 0 | 44,196 | 28.9 K to 44.2 K (+52.86 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Grant | A | 0.00 | 15,284 | 0 | 42,696 | 27.4 K to 42.7 K (+55.76 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 9,156 | 0 | 32,143 | 23 K to 32.1 K (+39.83 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Grant | A | 0.00 | 15,284 | 0 | 49,696 | 34.4 K to 49.7 K (+44.41 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 93,550 | 0 | 246,691 | 153.1 K to 246.7 K (+61.09 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Grant | A | 0.00 | 7,439 | 0 | 15,394 | 8 K to 15.4 K (+93.51 %) |
| Nov 22 2019 | REPH | Recro Pharma, Inc. | Recro Pharma, Inc. | 10% Owner | Sell | J | 0.00 | 9,211,245 | 0 | 0 | 9.2 M to 0 (-100.00 %) |
| Nov 22 2019 | REPH | Recro Pharma, Inc. | Recro Pharma, Inc. | 10% Owner | Buy | J | 0.00 | 9,211,145 | 0 | 9,211,245 | 100 to 9.2 M (+9,211,145.00 %) |
| Jun 07 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | M | 0.00 | 2,500 | 0 | 5,000 | |
| Jun 07 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 9.55 | 719 | 6,866 | 31,529 | 32.2 K to 31.5 K (-2.23 %) |
| Jun 07 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Buy | M | 0.00 | 2,500 | 0 | 32,248 | 29.7 K to 32.2 K (+8.40 %) |
| May 21 2019 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Buy | P | 9.00 | 40,000 | 360,000 | 1,104,546 | 1.1 M to 1.1 M (+3.76 %) |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 2.47 | 123,500 | 305,045 | 0 | |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Sell | S | 8.89 | 21,306 | 189,381 | 198,141 | 219.4 K to 198.1 K (-9.71 %) |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Sell | S | 8.89 | 123,500 | 1,097,915 | 219,447 | 342.9 K to 219.4 K (-36.01 %) |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 2.47 | 123,500 | 305,045 | 342,947 | 219.4 K to 342.9 K (+56.28 %) |
| May 13 2019 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
| May 13 2019 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Grant | A | 0.00 | 7,955 | 0 | 28,212 | 20.3 K to 28.2 K (+39.27 %) |
| May 10 2019 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
| May 10 2019 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Grant | A | 0.00 | 7,955 | 0 | 28,912 | 21 K to 28.9 K (+37.96 %) |
| May 10 2019 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
| May 10 2019 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 7,955 | 0 | 27,412 | 19.5 K to 27.4 K (+40.89 %) |
| May 10 2019 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
| May 10 2019 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 7,955 | 0 | 22,987 | 15 K to 23 K (+52.92 %) |
| May 10 2019 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
| May 10 2019 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 7,955 | 0 | 27,412 | 19.5 K to 27.4 K (+40.89 %) |
| May 10 2019 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
| May 10 2019 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Grant | A | 0.00 | 7,955 | 0 | 7,955 | 0 to 8 K |
| Mar 27 2019 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Director | Option Exercise | A | 6.41 | 20,000 | 128,200 | 20,000 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 10,000 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 7.99 | 171,184 | 1,367,760 | 171,184 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 7.99 | 1,425 | 11,386 | 214,384 | 215.8 K to 214.4 K (-0.66 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 215,809 | 210.8 K to 215.8 K (+2.37 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 35,801 | 0 | 210,809 | 175 K to 210.8 K (+20.46 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Option Exercise | M | 0.00 | 6,400 | 0 | 12,800 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Option Exercise | A | 7.99 | 60,592 | 484,130 | 60,592 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Payment of Exercise | F | 7.99 | 1,782 | 14,238 | 44,063 | 45.8 K to 44.1 K (-3.89 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Buy | M | 0.00 | 6,400 | 0 | 45,845 | 39.4 K to 45.8 K (+16.23 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Grant | A | 0.00 | 12,672 | 0 | 39,445 | 26.8 K to 39.4 K (+47.33 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | A | 7.99 | 53,859 | 430,333 | 53,859 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 7.99 | 1,880 | 15,021 | 28,155 | 30 K to 28.2 K (-6.26 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 5,750 | 0 | 30,035 | 24.3 K to 30 K (+23.68 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 11,264 | 0 | 24,285 | 13 K to 24.3 K (+86.51 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Payment of Exercise | F | 7.41 | 1,702 | 12,612 | 26,773 | 28.5 K to 26.8 K (-5.98 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 7.41 | 979 | 7,254 | 13,021 | 14 K to 13 K (-6.99 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 7.41 | 4,223 | 31,292 | 175,008 | 179.2 K to 175 K (-2.36 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 7.41 | 4,223 | 31,292 | 175,008 | 179.2 K to 175 K (-2.36 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 7.41 | 979 | 7,254 | 13,021 | 14 K to 13 K (-6.99 %) |
| Jun 07 2018 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | M | 0.00 | 2,500 | 0 | 7,500 | |
| Jun 07 2018 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Buy | M | 0.00 | 2,500 | 0 | 14,000 | 11.5 K to 14 K (+21.74 %) |
| May 24 2018 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 5.51 | 25,000 | 137,750 | 2,048,025 | 2.1 M to 2 M (-1.21 %) |
| May 24 2018 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 5.65 | 50,000 | 282,500 | 2,073,025 | 2.1 M to 2.1 M (-2.36 %) |
| May 24 2018 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 6.00 | 45,700 | 274,200 | 2,123,025 | 2.2 M to 2.1 M (-2.11 %) |
| May 24 2018 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 5.99 | 38,000 | 227,620 | 2,168,725 | 2.2 M to 2.2 M (-1.72 %) |
| May 24 2018 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 5.84 | 29,300 | 171,112 | 2,206,725 | 2.2 M to 2.2 M (-1.31 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | M | 0.00 | 13,274 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | Ashton William | Director | Buy | M | 0.00 | 13,274 | 0 | 19,457 | 6.2 K to 19.5 K (+214.69 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Option Exercise | M | 0.00 | 13,274 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Buy | M | 0.00 | 13,274 | 0 | 20,257 | 7 K to 20.3 K (+190.09 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | M | 0.00 | 13,274 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Buy | M | 0.00 | 13,274 | 0 | 26,457 | 13.2 K to 26.5 K (+100.69 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | M | 0.00 | 13,274 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Buy | M | 0.00 | 13,274 | 0 | 19,457 | 6.2 K to 19.5 K (+214.69 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Option Exercise | M | 0.00 | 13,274 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Option Exercise | M | 0.00 | 13,274 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Buy | M | 0.00 | 13,274 | 0 | 20,957 | 7.7 K to 21 K (+172.77 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Buy | M | 0.00 | 13,274 | 0 | 20,957 | 7.7 K to 21 K (+172.77 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | M | 0.00 | 8,849 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | M | 0.00 | 8,849 | 0 | 0 | |
| May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Buy | M | 0.00 | 8,849 | 0 | 15,032 | 6.2 K to 15 K (+143.12 %) |
| May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Buy | M | 0.00 | 8,849 | 0 | 15,032 | 6.2 K to 15 K (+143.12 %) |
| May 08 2018 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Grant | A | 0.00 | 6,183 | 0 | 7,683 | 1.5 K to 7.7 K (+412.20 %) |
| May 08 2018 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Grant | A | 0.00 | 6,183 | 0 | 6,183 | 0 to 6.2 K |
| May 08 2018 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Grant | A | 0.00 | 6,183 | 0 | 6,983 | 800 to 7 K (+772.88 %) |
| May 08 2018 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 6,183 | 0 | 6,183 | 0 to 6.2 K |
| May 08 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 6,183 | 0 | 6,183 | 0 to 6.2 K |
| May 08 2018 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Grant | A | 0.00 | 6,183 | 0 | 13,183 | 7 K to 13.2 K (+88.33 %) |
| May 08 2018 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
| May 08 2018 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 6,183 | 0 | 6,183 | 0 to 6.2 K |